[HTML][HTML] Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy
Y Lebranchu, F Bridoux, M Büchler, Y Le Meur… - American Journal of …, 2002 - Elsevier
Acute graft rejection remains a major problem in renal transplant recipients, and there is no
consensus on the optimal immunosuppressive strategy. Immunoprophylaxis with
Thymoglobulin® or basiliximab has significantly reduced the incidence of acute rejection
episodes and graft loss following kidney transplantation. This open, randomized, multicenter
study investigated the efficacy and tolerability of basiliximab (20 mg day 0–day 4) plus early
cyclosporine from day 0 (n= 50) compared with Thymoglobulin® plus delayed cyclosporine …
consensus on the optimal immunosuppressive strategy. Immunoprophylaxis with
Thymoglobulin® or basiliximab has significantly reduced the incidence of acute rejection
episodes and graft loss following kidney transplantation. This open, randomized, multicenter
study investigated the efficacy and tolerability of basiliximab (20 mg day 0–day 4) plus early
cyclosporine from day 0 (n= 50) compared with Thymoglobulin® plus delayed cyclosporine …